New and updated respiratory syncytial virus (RSV) resources
Home / News & Opportunities / Latest news / Current post
August 13, 2025
The Australian Government Department of Health, Disability and Aging (the department) has released a number of updated resources to support the correct administration of RSV vaccines and monoclonal antibodies.
A single dose of the RSV vaccine, Abrysvo®, is recommended for women at 28 to 36 weeks of pregnancy and is available for free through the National Immunisation Program (NIP).
- Arexvy® must not be administered to pregnant women.
- Victoria is offering the RSV monoclonal antibody, Beyfortus™ (Nirsevimab) for free to eligible infants and children.
- Abrysvo® and Arexvy® must not be administered to infants or children.
- The department has produced a poster outlining the correct administration of RSV vaccines and monoclonal antibodies by cohort.
Updated resources include:
- RSV vaccine and monoclonal antibody poster – to facilitate appropriate choice of product
- RSV provider advice fact sheet
- RSV consumer advice fact sheet
- RSV frequently asked questions fact sheet.
For more information visit - Respiratory syncytial virus (RSV) vaccine | Australian Government Department of Health, Disability and Ageing
Latest news
The Victorian and Tasmanian Primary Health Network Alliance (VTPHNA) is now the PHN Southern Alliance, following the welcome admission of Adelaide Primary Health Network. The Alliance now comprises eight PHNs operating across three states.
Childhood vaccination coverage is rising, with the latest National Centre for Immunisation Research and Surveillance (NCIRS) influenza data reporting a national increase of children vaccinated with at least one influenza vaccine.
In Victoria, cases of influenza (flu) and COVID-19 are increasing, while respiratory syncytial virus (RSV) cases remain high after peaking in July. Health service visits for respiratory illnesses have also been increasing.
